Analysis of an unselected patient cohort with advanced colorectal carcinoma from a maximum care center
Background/Aim: Systemic treatment for metastatic colorectal cancer (CRC) includes chemotherapy in combination with a targeted antibody. Novel targeted therapies and immunotherapies are introduced for specific molecular subgroups. Prognostic relevant determinants are still under investigation. Patie...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2023
|
| In: |
Anticancer research
Year: 2023, Volume: 43, Issue: 12, Pages: 5589-5596 |
| ISSN: | 1791-7530 |
| DOI: | 10.21873/anticanres.16761 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.21873/anticanres.16761 Verlag, lizenzpflichtig, Volltext: https://ar.iiarjournals.org/content/43/12/5589/tab-article-info 
|
| Author Notes: | Xin-Wen Zhang, Jutta Mohr, Niels Halama and Ronald Koschny |
| Summary: | Background/Aim: Systemic treatment for metastatic colorectal cancer (CRC) includes chemotherapy in combination with a targeted antibody. Novel targeted therapies and immunotherapies are introduced for specific molecular subgroups. Prognostic relevant determinants are still under investigation. Patients and Methods: Systemic therapies of an unselected patient cohort with metastatic CRC were retrospectively analyzed. Treatment outcome was evaluated according to time-to-next-treatment (TTNT) and frequency of conversion surgery and compared between subgroups stratified by primary tumor side, molecular profile, sex and age, and metastases sites. Results: More than 50% of patients with locally advanced or metastatic CRC underwent secondary resection after first-line systemic therapy. Rectum carcinoma had the best prognosis under anti-EGFR-antibody treatment. Female patients had a worse prognosis than male patients in late disease stage. Young patients demonstrated poor response to systemic therapy, but a high rate of conversion surgeries. Conversely, elderly patients benefited from systemic therapy but underwent surgery less frequently. Liver and lung metastases had a worse prognosis than other metastases sites, whereas lung metastases were more likely to be resected than liver metastases in early disease stage. Conclusion: Patient age, sex, primary tumor localization, and metastatic sites are prognostic factors that could guide future treatment decisions for the therapy of metastatic CRC. |
|---|---|
| Item Description: | Gesehen am 08.01.2025 Online veröffentlicht: 29. November 2023 |
| Physical Description: | Online Resource |
| ISSN: | 1791-7530 |
| DOI: | 10.21873/anticanres.16761 |